TheScreener - Genomic Health Inc. (GHDX) Increased risk weighs on GENOMIC HEALTH INCO., penalising its rating down to Slightly Negative

Report

TheScreener

EUR 14.10 For Business Accounts Only

Increased risk weighs on GENOMIC HEALTH INCO., penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of GENOMIC HEALTH INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date October 25, 2019, the closing price was USD 67.86 and its target price was estimated at USD 55.07.

26/10/2019 6 EN

Underlying

Genomic Health Inc.

Genomic Health provides genomic information to personalize cancer treatment decisions. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make treatment decisions. The company provides its tissue-based invasive breast, ductal carcinoma in situ (DCIS), prostate and colon Oncotype DX tests as clinical laboratory services, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a gene expression profile expressed as a single quantitative score. The company also provides an Oncotype DX test for patients with DCIS, a pre-invasive form of breast cancer.

See profile

US37244C1018 United States

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

Valens Research

UAFRS vs As Reported Weekly Highlights - 2019 10 31

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for RDWR, RMAX, and GHDX.

November 1, 2019 November 1, 2019 8 EN

Vermilion Research

Vital Signs: Actionable charts

Key Points: â€¢ Homebuilders remain a leadership Group in the Consumer Discretionary Sector (ex. MDC, LGIH, CCS, and BLD) â€¢ Insurance related names continue to be leadership. (ex. AJG, BRO, AON, and WLTW) â€¢ Technology continues to have a number of attractive technical charts. (ex. AMAT, LRCX, SGH, CEVA, MU, EVTC, CSGS, SAIC, COHR, WDC, and STX)

EUR 47.02

September 5, 2019 September 5, 2019 22 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Increased risk weighs on GENOMIC HEALTH INCO., penalising its rating down to Slightly Negative

Empowering Investors

UAFRS vs As Reported Weekly Highlights - 2019 10 31

Vital Signs: Actionable charts

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe